SMTI Sanara MedTech Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 714256 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.8%
TTM net income YoY92.0%
TTM EPS YoY91.9%
Revenue 3-yr CAGR21.4%
Net income 3-yr CAGR—
Margins
Gross margin93.0%
Operating margin5.6%
Net margin-2.7%
FCF margin6.5%
EBITDA margin7.8%
Returns
ROE-43.7%
ROA-4.2%
ROIC (approx.)13.3%
Asset turnover1.56x
Leverage & solvency
Liabilities / assets89.4%
Debt / equity6.10x
Current ratio2.24x
Interest coverage0.86x
Cash quality & payout
Operating cash flow / net income-2.46x
Accruals ratio-14.6%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $103.12M | $86.67M |
| Cost of revenue | $7.52M | $8.14M |
| Gross profit | $95.60M | $78.53M |
| R&D expense | $5.07M | $2.83M |
| SG&A expense | $78.72M | $71.67M |
| Operating income | $7.30M | $1.26M |
| Interest expense | $6.76M | $3.13M |
| Pretax income | -$393,124 | -$1.89M |
| Income tax | — | $48,380 |
| Net income | -$37.56M | -$9.66M |
| EBITDA | $11.25M | $6.18M |
| EPS (basic) | -4.36 | -1.14 |
| EPS (diluted) | -4.36 | -1.14 |
| Weighted avg. shares (diluted) | 8.62M | 8.48M |
| Balance sheet | ||
| Cash & equivalents | $16.58M | $15.88M |
| Receivables | $12.00M | — |
| Inventory | $3.95M | $2.75M |
| Current assets | $33.54M | $33.31M |
| PP&E, net | $456,962 | $432,317 |
| Goodwill | $3.60M | $3.60M |
| Intangibles | $18.64M | $23.48M |
| Total assets | $72.94M | $88.09M |
| Current liabilities | $18.63M | $15.29M |
| Long-term debt | $45.97M | $30.69M |
| Total debt | $45.97M | $30.69M |
| Total liabilities | $67.01M | $49.18M |
| Shareholders' equity | $5.94M | $39.40M |
| Net debt | $29.39M | $14.81M |
| Shares outstanding | 8.95M | 8.75M |
| Cash flow statement | ||
| Operating cash flow | $6.79M | -$23,784 |
| Capital expenditure | $4.63M | $205,848 |
| Free cash flow | $2.16M | -$229,632 |
| Investing cash flow | -$14.97M | -$6.61M |
| Financing cash flow | $8.89M | $17.37M |
| Depreciation & amortization | $3.95M | $4.92M |
| Stock-based compensation | $5.15M | $4.44M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.